GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halozyme Therapeutics Inc (NAS:HALO) » Definitions » Cyclically Adjusted Book per Share

Halozyme Therapeutics (Halozyme Therapeutics) Cyclically Adjusted Book per Share : $1.03 (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Halozyme Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Halozyme Therapeutics's adjusted book value per share for the three months ended in Dec. 2023 was $0.661. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $1.03 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Halozyme Therapeutics's average Cyclically Adjusted Book Growth Rate was 14.40% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 17.80% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 19.70% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 14.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Halozyme Therapeutics was 31.00% per year. The lowest was -5.30% per year. And the median was 13.75% per year.

As of today (2024-04-28), Halozyme Therapeutics's current stock price is $38.57. Halozyme Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $1.03. Halozyme Therapeutics's Cyclically Adjusted PB Ratio of today is 37.45.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Halozyme Therapeutics was 79.11. The lowest was 19.48. And the median was 43.24.


Halozyme Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Halozyme Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halozyme Therapeutics Cyclically Adjusted Book per Share Chart

Halozyme Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.55 0.63 0.77 0.90 1.03

Halozyme Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.90 0.92 0.95 1.01 1.03

Competitive Comparison of Halozyme Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Halozyme Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Halozyme Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Halozyme Therapeutics's Cyclically Adjusted PB Ratio falls into.



Halozyme Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Halozyme Therapeutics's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book= Book Value per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.661/129.4194*129.4194
=0.661

Current CPI (Dec. 2023) = 129.4194.

Halozyme Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201403 0.536 99.695 0.696
201406 0.441 100.560 0.568
201409 0.318 100.428 0.410
201412 0.329 99.070 0.430
201503 0.295 99.621 0.383
201506 0.393 100.684 0.505
201509 0.249 100.392 0.321
201512 0.336 99.792 0.436
201603 0.228 100.470 0.294
201606 0.077 101.688 0.098
201609 -0.093 101.861 -0.118
201612 -0.251 101.863 -0.319
201703 -0.451 102.862 -0.567
201706 0.410 103.349 0.513
201709 0.509 104.136 0.633
201712 1.459 104.011 1.815
201803 1.842 105.290 2.264
201806 1.768 106.317 2.152
201809 1.659 106.507 2.016
201812 1.720 105.998 2.100
201903 1.789 107.251 2.159
201906 1.783 108.070 2.135
201909 1.675 108.329 2.001
201912 0.671 108.420 0.801
202003 0.429 108.902 0.510
202006 0.772 108.767 0.919
202009 0.731 109.815 0.862
202012 1.119 109.897 1.318
202103 0.471 111.754 0.545
202106 0.842 114.631 0.951
202109 1.998 115.734 2.234
202112 1.432 117.630 1.576
202203 1.887 121.301 2.013
202206 2.129 125.017 2.204
202209 0.717 125.227 0.741
202212 1.256 125.222 1.298
202303 0.500 127.348 0.508
202306 1.145 128.729 1.151
202309 1.887 129.860 1.881
202312 0.661 129.419 0.661

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Halozyme Therapeutics  (NAS:HALO) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Halozyme Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=38.57/1.03
=37.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Halozyme Therapeutics was 79.11. The lowest was 19.48. And the median was 43.24.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Halozyme Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Halozyme Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Halozyme Therapeutics (Halozyme Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
12390 El Camino Real, San Diego, CA, USA, 92130
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Executives
Michael J. Labarre officer: SVP, Chief Technical Officer 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Helen Torley director, officer: President and CEO C/O ONYX PHARMACEUTICALS, INC., 249 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
James M Daly director INCYTE CORPORATION EXPERIMENTAL STATION, RTE 141 & HENRY CLAY RD. BLDG E336, WILMINGTON DE 19880
Jeffrey William Henderson director 7000 CARDINAL PLACE, DUBLIN OH 43017
Nicole Labrosse officer: SVP, Chief Financial Officer 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Barbara Gayle Duncan director C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
Matthew L. Posard director 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Akiko Moni Miyashita director 20725 S. WESTERN AVENUE, SUITE 136, TORRANCE CA 90501
Mark Howard Snyder officer: SVP, General Counsel 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Matsui Connie director 3030 CALLAN RD, SAN DIEGO CA 92121
Jean-pierre Bizzari director 235 LAUREL LN, HAVERFOLD PA 19041
Kenneth J Kelley director 1331 HILLVIEW DRIVE, MENLO PARK CA 94025
Elaine D Sun officer: SVP, Chief Financial Officer 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Masaru Matsuda officer: SVP, General Counsel 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Benjamin Hickey officer: SVP, Chief Commerical Officer C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121